Show Notes
We dive into the recognition and management of blast crisis.
Hosts:
Sadakat Chowdhury, MD
Brian Gilberti, MD
https://media.blubrry.com/coreem/content.blubrry.com/coreem/Blast_Crisis.mp3
Download
2 Comments
Tags: Hematology, Oncology
Show Notes
Topic Overview
Blast crisis is an oncologic emergency, most commonly seen in chronic myeloid leukemia (CML).
Defined by:
>20% blasts in peripheral blood or bone marrow.
May include extramedullary blast proliferation.
Without treatment, median survival is only 3–6 months.
Pathophysiology & Associated Conditions
Usually occurs in CML, but also in:
Myeloproliferative neoplasms (MPNs)
Myelodysplastic syndromes (MDS)
Transition from chronic to blast phase often reflects disease progression or treatment resistance.
Risk Factors
10% of CML patients progress to blast crisis.
Risk increased in:
Patients refractory to tyrosine kinase inhibitors (e.g., imatinib).
Those with Philadelphia chromosome abnormalities.
WBC >100,000, which increases risk for leukostasis.
Clinical Presentation
Symptoms often stem from pancytopenia and leukostasis:
Anemia: fatigue, malaise.
Functional neutropenia: high WBC count, but increased infection/sepsis risk.
Thrombocytopenia: bleeding, bruising.
Leukostasis/hyperviscosity effects by system:
Neurologic: confusion, visual changes, stroke-like symptoms.
Cardiopulmonary: ARDS, myocardial injury.
Others: priapism, limb ischemia, bowel infarction.
Rapid deterioration is common — early recognition is critical.
Diagnostic Workup
CBC with differential: assess blast % and cytopenias.
Peripheral smear and manual diff: confirm immature blasts.
CMP: screen for tumor lysis syndrome:
Elevated potassium, phosphate, uric acid.
Low calcium.
LDH & uric acid: markers of high cell turnover.
Coagulation studies (PT, PTT): assess for DIC.
Definitive tests (done inpatient): bone marrow biopsy, flow cytometry.
Emergency Department Management
Resuscitation & ABCs: oxygen, IV fluids, vitals monitoring.
Avoid aggressive transfusions:
Risk of hyperviscosity with PRBCs and platelets.
Initiate broad-spectrum antibiotics early:
High suspicion for sepsis in functionally neutropenic patients.
Consider antifungals for prolonged febrile neutropenia.
Cytoreduction strategies:
Hydroxyurea to lower WBCs quickly.
Tyrosine kinase inhibitors (TKIs).
High-dose chemotherapy.
Early consultation with hematology/oncology is essential.
Mutation testing may guide targeted therapy.
Prognosis
Without treatment: median survival ~3 months.
With treatment:
Potential survival >1 year.
Best outcomes in patients who enter a second chronic phase and undergo allogeneic stem cell transplant.
Ethical & Logistical Considerations
Treatment may involve aggressive interventions with serious side effects.
Important to assess:
Patient goals of care.
Capacity for informed consent.
Resource limitations:
Not all hospitals have oncology services.
Patients may require transfer over long distances.
Emphasize early, transparent discussions with patients and families.
Top 3 Take-Home Points
Recognize early: Look for cytopenias, leukostasis, and rapid clinical decline.
Resuscitate appropriately: Start antibiotics; be cautious with transfusions.
Call for help: Early hematology/oncology involvement is essential for definitive care.
Read More
More from Core EM - Emergency Medicine Podcast
Tickborne illnesses in the ED: attachment time, the rash, the smear, prophylaxis, & treatment.
Acute diarrhea in the ED: stool testing, treatment, and a spotlight on Cyclospora.
Superwarfarin toxicity: recognition, reversal, and prolonged vitamin K therapy.
Group A strep in the pediatric ED: from strep throat to invasive disease and toxic shock.
A guide to diagnosing, imaging, and managing acute renal colic and nephrolithiasis in the ED.